Celldex Therapeutics Share Price Today
(NASDAQ: CLDX)

Name: Celldex Therapeutics Share Price Today (NASDAQ: CLDX) - Celldex Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Celldex Therapeutics share price is $18.3 & ₹1,564.01 as on 18 Apr 2025, 2.30 'hrs' IST

$18.3

▲

0.5

(2.81%)

Market is closed - opens 7 PM, 21 Apr 2025

View live Celldex Therapeutics share price in Dollar and Rupees. Guide to invest in Celldex Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Celldex Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Celldex Therapeutics share price movements

Today's Low: $17.59
Today's High: $18.37
$18.30
3.88%
Downside
Day's Volatility :4.25%
Upside
0.38%
52 Weeks Low: $14.40
52 Weeks High: $47.00
$18.30
21.31%
Downside
52 Weeks Volatility :69.36%
Upside
61.06%

Celldex Therapeutics (CLDX) Returns

Period	Celldex Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-25.64%	-2.8%	0.0%
6 Months	-36.21%	-11.0%	0.0%
1 Year	-51.82%	-1.9%	0.0%
3 Years	-45.92%	-1.5%	-12.9%

Celldex Therapeutics (CLDX) Key Statistics

in dollars & INR

Previous Close	$17.8
Open	$17.72
Today's High	$18.37
Today's Low	$17.59
Market Capitalization	$1.2B
Today's Volume	$457.9K
52 Week High	$47.0
52 Week Low	$14.4
Revenue TTM	$7.0M
EBITDA	$-191.9M
Earnings Per Share (EPS)	$-2.45
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-26.84%

How to invest in Celldex Therapeutics Stock (CLDX) from India?

It is very easy for Indian residents to invest directly in Celldex Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Celldex Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Celldex Therapeutics or CLDX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Celldex Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Celldex Therapeutics shares which would translate to 0.047 fractional shares of Celldex Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Celldex Therapeutics, in just a few clicks!

Returns in Celldex Therapeutics (CLDX) for Indian investors in Rupees

The Celldex Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Celldex Therapeutics investment value today

Current value as on today

₹50,524

Returns

₹49,476

(-49.48%)

Returns from Celldex Therapeutics Stock

₹51,817 (-51.82%)

Dollar Returns

₹2,341 (+2.34%)

Indian investors sentiment towards Celldex Therapeutics (CLDX)

-54%

Period: Mar 19, 2025 to Apr 18, 2025. Change in 30 Days versus previous period

Search interest for Celldex Therapeutics Stock from India on INDmoney has decreased by -54% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Celldex Therapeutics

Wellington Management Company LLP
13.52%
BlackRock Inc
8.26%
Kynam Capital Management, LP
7.63%
FMR Inc
7.32%
Vanguard Group Inc
5.85%
Eventide Asset Management, LLC
5.65%

Analyst Recommendation on Celldex Therapeutics

Rating

Trend

Buy

85%Buy

14%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Celldex Therapeutics(by analysts ranked 0 to 5 stars)

Analyst Forecast on Celldex Therapeutics Stock (CLDX)

What analysts predicted

Upside of 239.25%

Target:

$62.08

Current:

$18.30

Insights on Celldex Therapeutics Stock (Ticker Symbol: CLDX)

Price Movement
In the last 7 days, CLDX stock has moved up by 5.7%
Decreasing Revenue
Revenue is down for the last 2 quarters, 3.19M → 1.17M (in $), with an average decrease of 63.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, -32.80M → -47.09M (in $), with an average decrease of 12.9% per quarter
CLDX vs ONC (1 yr)
In the last 1 year, Beone Medicines Ltd has given 76.1% return, outperforming this stock by 129.2%
CLDX vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 28.9% return, outperforming this stock by 77.0%
Price to Sales
ForCLDX every $1 of sales, investors are willing to pay $167.9, whereas for Beone Medicines Ltd, the investors are paying $6.4 for every $1 of sales.

Celldex Therapeutics Technicals Summary

Sell

Neutral

Buy

Celldex Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Celldex Therapeutics (CLDX) Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Celldex Therapeutics, Inc.	-10.46%	-36.21%	-51.82%	-45.92%	779.81%
Regeneron Pharmaceuticals, Inc.	-17.1%	-41.85%	-37.2%	-21.74%	-0.85%
Beone Medicines Ltd	-13.12%	5.03%	78.34%	40.23%	43.44%
Vertex Pharmaceuticals Incorporated	-4.76%	2.3%	24.05%	71.43%	78.99%
Alnylam Pharmaceuticals, Inc.	-9.09%	-19.67%	62.43%	39.66%	61.91%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Celldex Therapeutics, Inc.	NA	NA	0.0	-3.27	-0.27	-0.19	NA	11.25
Regeneron Pharmaceuticals, Inc.	14.33	14.33	0.89	41.63	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.09	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.37	17.97	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.81	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Celldex Therapeutics, Inc.	Buy	$1.2B	779.81%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$60.1B	-0.85%	14.33	31.07%
Beone Medicines Ltd	NA	$27.0B	43.44%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.9B	78.99%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$29.8B	61.91%	NA	-12.37%

Celldex Therapeutics Dividend announcements

Celldex Therapeutics Earnings
Celldex Therapeutics’s price-to-earnings ratio stands at None

About Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.

Organization	Celldex Therapeutics
Employees	186
CEO	Mr. Anthony S. Marucci M.B.A.
Industry	Health Technology

Management People of Celldex Therapeutics

Name	Title
Mr. Anthony S. Marucci M.B.A.	Founder, President, CEO & Director
Dr. Tibor Keler Ph.D.	Founder, Chief Scientific Officer & Executive VP
Mr. Sam Martin CPA	Senior VP, CFO, Secretary & Treasurer
Dr. Margo Heath-Chiozzi M.D.	Senior Vice President of Regulatory Affairs
Dr. Diane C. Young M.D.	Senior VP & Chief Medical Officer
Prof. Joseph P. Schlessinger Ph.D.	Co-Founder & Member of Scientific Advisory Board
Ms. Sarah Cavanaugh	Senior Vice President of Corporate Affairs & Administration
Mr. Freddy A. Jimenez Esq.	Senior VP & General Counsel
Dr. Ronald A. Pepin	Chief Business Officer & Senior VP
Ms. Elizabeth Crowley	Chief Product Development Officer & Senior VP

Important FAQs about investing in CLDX Stock from India :

What is Celldex Therapeutics share price today?

Celldex Therapeutics share price today stands at $18.30, Open: $17.72 ; Previous Close: $17.80 ; High: $18.37 ; Low: $17.59 ; 52 Week High: $47.00 ; 52 Week Low: $14.40.

The stock opens at $17.72, after a previous close of $17.80. The stock reached a daily high of $18.37 and a low of $17.59, with a 52-week high of $47.00 and a 52-week low of $14.40.

Can Indians buy Celldex Therapeutics shares?

Yes, Indians can invest in the Celldex Therapeutics (CLDX) from India.

With INDmoney, you can buy Celldex Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Celldex Therapeutics at zero transaction cost.

How can I buy Celldex Therapeutics shares from India?

It is very easy to buy Celldex Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Celldex Therapeutics (CLDX) be purchased?

Yes, you can buy fractional shares of Celldex Therapeutics with INDmoney app.

What are the documents required to start investing in Celldex Therapeutics stocks?

To start investing in Celldex Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.